From eugenics to therapeutics: The impact of opposition on the development of gene therapy in the USA

The Social Management of Genetic Engineering

Volumn , Issue , 2019, Pages 139-157

  Martin, Paul ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85082453243     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780429423499-8     Document Type: Chapter

References (52)

1. Ad Hoc Review Committee, Recombinant DNA Advisory Committee (1995) Executive summary of findings and recommendations, 8th September 1995, Office of the Director, NIH, Bethesda, USA.
2. Anderson, W.F. and Fletcher, J.C. (1980) ‘Gene therapy in human beings: when is it ethical to begin?', New England Journal of Medicine, vol. 303, no. 22, pp. 1293-97.
3. Anonymous (1995) ‘A triumph of hype over experience?' Economist, December 16th, pp. 111-12.
4. Aposhian, H.V. (1970) ‘The Use of DNA for Gene Therapy -the Need, Experimental Approach, and Implications’, Perspectives in Biology and Medicine, Autumn, 1970, p. 99.
5. Beckmann, J. (1984) ‘Germ-line gene therapy a misnomer?' (Letter), Nature, vol. 312, p. 408.
6. Bijker, W.E. (1995) Of Bicycles, Bakelites and Bulbs: Towards a Theory of Sociotechnical Change, MIT, Cambridge, Massachusetts.
7. Bud, R. (1993) The Uses of Life: A History of Biotechnology, Cambridge University Press, Cambridge.
8. Budiansky, S. (1983) ‘Churches against germ changes’, Nature, vol. 303, p. 563.
9. Budiansky, S. (1984) ‘Watch on human experiments’, Nature, vol. 307, p. 584.
10. Busch, L. and Tanaka, K. (1996) ‘Rites of passage: constructing quality’. Science, Technology, & Human Values, vol. 21, no. I, pp. 3-27.
11. Callahan, D. (1979) ‘The Moral Career of Genetic Engineering’, Hastings Center Reports, no. 9, p. 21.
12. Callon, M. (1986) ‘The Sociology of an Actor network: The Case of the Electric Vehicle’, in Mapping the Dynamics of Science and Technology: Sociology of Science in the Real World, Callon, M., et al. (eds.), Macmillan, Basingstoke, pp. 19-34.
13. Capron, A.M. (1990) ‘The Impact of the Report Splicing Life’, Human Gene Therapy, vol. 1, no. 1, pp. 69-71.
14. Cook-Deegan, R.M. (1990) ‘Human Gene Therapy and Congress’, Human Gene Therapy vol 1, no. 1, pp. 163-70.
15. Culliton, B. (1986) ‘NIH Asked to Tighten Gene Therapy Rules’, Science, vol. 233, p. 1378.
16. Elzen, B., et al. (1996) ‘Socio-Technical Networks: How a Technology Studies Approach May Help to Solve Problems Related to Technical Change’, Social Studies of Science, vol. 26, pp. 95-141.
17. Foundation On Economic Trends (1983) ‘The theological letter concerning the moral arguments against genetic engineering of the human germ-line cells’, in Reprinted in Taking Sides: Clashing Views on Controversial Bio-Ethical Issues, Dushkin, GCT, pp. 276-80.
18. Fox, J.L. (1997) ‘NIHRAC: Disguised retirement of vigorous future?' Nature Biotechnology, vol. 15, no. 1, pp. 11-12.
19. Friedmann, T. and Roblin, R. (1972) ‘Gene therapy for human genetic disease?', Science, vol. 175, pp. 949-55.
20. Gavaghan, H. (1994) ‘Gene advisory group switches focus to ethical issues’, Nature, no. 371, pp. 468.
21. Haldane, J.B.S. (1923) ‘Daedalus or science and the future’, in K.R. Dronamraju (ed.) Haldane’s Daedalus Revisited, Oxford University press, Oxford.
22. Jacobs, P. (1980) ‘Human engineering: pioneer genetic implants revealed’, Los Angeles Times, Oct. 8th, p. 1.
23. Law, J. (1987) ‘On the social explanation of technical change: the case of the Portuguese maritime expansion’, Technology and Culture, no. 28, pp. 227-52.
24. Luria, S. (1965) ‘From the discussion in “Evaluation of Applications to Man”, in T.M. Sonneborn (ed.) The Control of Human Heredity and Evolution. Macmillan, New York, p. 123.
25. Luria, S.E. (1969) ‘Modern biology: A terrifying power’, Nation, Oct. 20th, p. 406.
26. Lyon, J; Gorner, P. (1995) Altered Fates: Gene Therapy and the Retooling of Human Life, Norton and Company, New York.
27. MacKenzie, D. and Wajcman, J. (1985) The Social Shaping of Technology, Open University Press, Milton Keynes.
28. Martin, P. (1995) ‘The American gene therapy industry and the social shaping of a new technology’, The Genetic Engineer and Biotechnologist, vol. 15, p. 155-67.
29. Martin, P. and Thomas, S. (1996) The Development of Gene Therapy in Europe and the United States: A Comparative Analysis, STEEP Special Report, no 5, Science Policy Research Unit, University of Sussex, Brighton.
30. Muller, H. (1965) ‘Means and aims in human genetic betterment’, in T.M. Sonneborn (ed.) The Control of Human Heredity and Evolution, Macmillan, New York, pp. 104-10.
31. National Institutes of Health (1985) ‘Points to consider in the design and submission of human somatic-cell gene therapy protocols’, Federal Register, no. 50, pp. 33463-467.
32. Nirenberg, M.W. (1967) ‘Will society be prepared? Science, vol. 157, no. 3789, p. 1.
33. Office of Technology Assessment (1984) Human Gene Therapy: Background Paper, US Congress, Office of Technology Assessment, OTA-BP-BA-32, Washington D.C. 105, p. 46.
34. President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioural Research (1980) Splicing Life: The Social and Ethical Issues of Genetic Engineering with Human Beings, US Government Printing Office, Washington DC.
35. Randall, C, et al. (1980) ‘Message from Three General Secretaries (of religious organizations representing Catholics, Jews and Protestants)', June 29th, 1980. Reprinted in Law, Science and Medicine (1984) University Casebook Series. Edited by J. Areen at al. Foundation Press Inc., Westbury, New York.
36. Ravetz, J. R. (1971) Scientific Knowledge and Its Social Problems, Oxford University Press, Oxford.
37. Recombinant DNA Advisory Committee (1985) Minutes of Meeting, May 3rd, 1985, Department of Health and Human Services, Public health Service, National Institutes of Health.
38. Rifkin, J. (1983) Algeny: A New Word -A New World, Penguin, New York.
39. Roberts, L. (1989) ‘Ethical questions haunt new genetic technology’, Science, no. 243, pp. 1134-36.
40. Rosenfeld, A. (1965) ‘Will Man direct his own evolution’, Life, vol. 59, no. 14.
41. Rostand, J. (1959) Can Man Be Modified?, Seeker and Warburg, London.
42. Schmerk Jr.H. (1981) ‘U.S. agency disciplines gene-splicing researcher’, Los Angeles Times, May 29th.
43. Shapiro, J., et al. (1969) ‘More alarms and exclusions’, Nature, no. 224, p. 1337.
44. Stapledon, W.O. (1930), Last and First Men, Methuen, London.
45. Szybalski, W. (1992) ‘Use of the HPRT gene and the HAT selection technique in DNA-mediated transformation of mammalian cells: first steps toward developing hybridoma techniques and gene therapy’, Bioessays, vol. 14, no. 7, pp. 495-500.
46. Tatum, E.L. (1958) ‘A case history in biomedical research’, in Nobel Lectures in Molecular Biology 1933-1975, Elsevier, New York, 1976.
47. Tatum, E.L. (1966a) ‘Molecular biology, nucleic acids and the future of medicine’, Perspectives in Biology and Medicine, Autumn, pp. 19-32.
48. Tatum, E. L. (1966b) ‘The possibility of manipulating genetic change’ in Genetics and the Future of Man: A Discussion at the Nobel Conference, R. Roslansky (ed.), North-Holland, Amsterdam, pp. 49-62.
49. Taylor.G.R. (1968) The Biological Time Bomb, New American Library, New York.
50. Van Lente, H. (1993) Promising Technology: The Dynamics of Expectations in Technological Developments, University of Twente, Enschede.
51. Wade, N. (1980) ‘UCLA gene therapy racked by friendly fire’, Science, vol. 210, pp. 509-11.
52. Wright, S. (1994) Molecular Politics: Developing American and British Regulatory Policy for Genetic Engineering 1972-1982, University of Chicago Press, Chicago.